Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways

Advanced hepatocellular carcinoma (HCC) results in generally poor clinical outcomes and necessitates better therapeutic strategies. Ivermectin, which is an existing anti‐parasitic drug, has been recently identified as a novel anti‐cancer drug. In line with previous efforts, this work demonstrates th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Haofeng, Zhou, Lin, Zuo, Hongping, Le, Wenjin, Hu, Jianfei, Zhang, Tiequan, Li, Mi, Yuan, Yufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107598/
https://www.ncbi.nlm.nih.gov/pubmed/35568994
http://dx.doi.org/10.1002/prp2.954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107598/
https://www.ncbi.nlm.nih.gov/pubmed/35568994
http://dx.doi.org/10.1002/prp2.954

Ejemplares similares